An observational study in Retinal Vascular Disorder and Macular Degeneration, sponsored by University of California, Los Angeles. Terminated at 1 site in United States. Open to participants aged 18 Years to 115 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by University of California, Los Angeles · Observational
The purpose of this study is to evaluate this AngioScan angiography software on patients with various retinal vascular disorders. The advanced OCT instrument is an FDA approved clinically used camera, but the AngioScan angiography software is not FDA approved. Investigators would like to know if this imaging device and software can improve the quality of images and visualization of imaged tissues and whether they are useful in the diagnosis and treatment of eye diseases. Images collected in this study may be compared to other images collected as part of standard of care on the same patient (OCT, FA, AF, Fundus).
1,473 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's enrollment of 150 is above the median of 106 across 421 observational studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects with retinal vascular abnormalities
Exclusion Criteria:
Subjects with various retina vascular disorders
Retinal vascular abnormalities imaged by OCT Angiography and en face analysis of macular disorders
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles